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Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative
disease that leads to the death of motor and cortical neurons. The
clinical manifestations of ALS are heterogenous, and efficacious treatments
to signiﬁcantly slow the progression of the disease are lacking. Cortical
hyper-excitability is observed pre-symptomatically across disease-causative
genetic variants, as well as in the early stages of sporadic ALS, and typically
precedes motor neuron involvement and overt neurodegeneration. The
causes of cortical hyper-excitability are not yet fully understood but is
mainly agreed to be an early event. The identiﬁcation of the nucleotide
repeat expansion (GGGGCC)n in the C9ORF72 gene has provided evidence
that ALS and another neurodegenerative disease, frontotemporal dementia
(FTD), are part of a disease spectrum with common genetic origins. ALS
and FTD are diseases in which synaptic dysfunction is reported throughout
disease onset and stages of progression. It has become apparent that
ALS/FTD-causative genes, such as C9ORF72, may have roles in maintaining the
normal physiology of the synapse, as mutations in these genes often manifest
in synaptic dysfunction. Here we review the dysfunctions of the central nervous
system synapses associated with the nucleotide repeat expansion in C9ORF72
observed in patients, organismal, and cellular models of ALS and FTD.
KEYWORDS

amyotrophic lateral sclerosis, frontotemporal dementia, synaptic dysfunction,
neurodegenerative disease, C9orf72

Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease
that leads to the death of motor neurons. The clinical manifestations of ALS are
heterogenous (Taylor et al., 2016; Abramzon et al., 2020; Bendotti et al., 2020; Masrori
and Van Damme, 2020), and efficacious treatments to significantly slow the progression
of the disease are lacking. Identification of genetic risk factors has provided evidence
that ALS and another neurodegenerative disease, frontotemporal dementia (FTD), are
part of a disease spectrum with common genetic origins. One such causative genetic
risk factor is the aberrant intronic (GGGGCC)n nucleotide repeat expansion (NRE) in
the C9ORF72 gene (C9). The C9-NRE has been identified as the most common genetic
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central nervous system synapses associated with the C9NRE observed in patients, organismal, and cellular models
of ALS and FTD. Furthermore, neuronal activity controls
proper neuronal development, synaptic function, and ultimately
health and survival of the individuals and organisms (Flavell
and Greenberg, 2008; Turrigiano, 2012; Yap and Greenberg,
2018). Activity-dependent pathways are essential for adaptivity
to external stimuli, whereas defects in components of these
pathways are associated with neurological disorders (Yap and
Greenberg, 2018).
ALS and FTD are diseases in which synaptic dysfunction
is reported throughout disease onset and stages of progression.
Synaptic dysfunction is an umbrella term that encompasses
alterations in the morphology of neurons at dendritic spines
or dendritic arborization, changes in electrophysiological
properties, such as amplitude or frequency of action potential
firing, membrane capacitance or resting membrane potential,
mishandling of intracellular calcium signaling, and modulation
of levels of synaptic proteins. Deficits in synaptic structure,
function, and synaptic protein levels are well-documented in
neurological diseases (Lepeta et al., 2016; Bae and Kim, 2017).
It has become more apparent that ALS/FTD-causative genes,
such as C9ORF72, may have roles in maintaining the normal
physiology of the synapse, as mutations in these genes often
manifest in synaptic dysfunction. For example, it is thought
that the C9-NRE can alter the neuronal excitability (Sareen
et al., 2013; Devlin et al., 2015; Starr and Sattler, 2018) and
thus could trigger a feed-forward loop of activity-dependent
dysfunctions. While there are few studies related to overt
changes in excitability in FTD patients, it has been shown
that deficits in functional neuronal networks occur (Lee et al.,
2014; Huber et al., 2021). Related to ALS, cortical hyperexcitability is observed pre-symptomatically across diseasecausative genetic variants, as well as in the early stages of
sporadic ALS, and typically precedes motor neuron involvement
and overt neurodegeneration (Vucic et al., 2008; Bae et al.,
2013; Geevasinga et al., 2015, 2016; Wainger and Cudkowicz,
2015; Walhout et al., 2015; Schanz et al., 2016; Brunet et al.,
2020). The causes of cortical hyper-excitability are not yet fully
understood but is mainly agreed to be an early event in disease
progression. Still, there is evidence that suggests an excitatoryinhibitory imbalance. Notably, modulation of neuronal activity
in ALS is a primary topic of interest, and the first FDAapproved drug for ALS, Riluzole, was shown to dampen
neuronal activity (Bellingham, 2011). Moreover, alterations
in glutamatergic neurotransmission have been identified as a
source of neuronal stress in ALS (Rosenblum and Trotti, 2017;
Armada-Moreira et al., 2020). Excess glutamate in the CSF of
ALS and FTD patients has been reported (Rothstein et al., 1990;
Palese et al., 2020), in addition to changes in glutamate receptor
subunits’ composition and function, which are described in
this review.

cause of ALS and FTD, and individuals with the C9-NRE
can have ALS, FTD, or both (Dejesus-Hernandez et al., 2011;
Renton et al., 2011). The NRE is suspected of leading to
neurodegeneration in three ways that may not be mutually
exclusive. The C9-NRE DNA can be transcribed into repeatcontaining RNA, which can form secondary structures such
as hair-pins and G-quadruplexes and thus sequester RNAbinding proteins critical for cell survival (Donnelly et al.,
2013; Haeusler et al., 2014; Burguete et al., 2015; Conlon
et al., 2016). Five distinct dipeptide repeat protein species
(DPRs); poly(GA), poly(GR), poly(GP), poly(PA), and poly(PR)
are unconventionally produced through repeat-associated nonAUG (RAN) translation of the pathogenic C9-NRE RNA in both
sense and antisense directions (Mori et al., 2013; Zu et al., 2013)
and confer neurotoxicity (Wen et al., 2014, 2017; Freibaum
and Taylor, 2017). Thirdly, there is loss of C9ORF72 RNA and
protein levels due to the transcription-repressive effect of the
C9-NRE (Dejesus-Hernandez et al., 2011; Donnelly et al., 2013).
Other genetic risk factors on the ALS-FTD disease spectrum
include mutations in DNA/RNA-binding proteins TAR DNAbinding protein 43 (TARDBP, TDP-43) and fused in sarcoma
(FUS), both of which are predominantly nuclear proteins but
have recently been found to have a function at the synapse (Ling,
2018). When mutated, FUS and TDP-43 are frequently found
in cytoplasmic inclusions and/or are lost from the nucleus in
patient postmortem tissue (Dormann and Haass, 2011). TDP43 is further implicated in the pathogenesis of ALS and FTD, as
loss of nuclear TDP-43 and cytoplasmic aggregates are the most
common pathological hallmarks of both sporadic and familial
ALS and FTD in postmortem tissues (Suk and Rousseaux, 2020).
Genetic variations in the superoxide dismutase 1 gene (SOD1),
involved in the cellular antioxidant defense and homeostasis of
reactive oxygen species (Bowling et al., 1993; Rosen et al., 1993),
are other risk factors for ALS. Apart from SOD1 localization in
mitochondria, which are found at synapses, SOD1 has not been
reported to have a specific function at the synapse. Still, the loss
of function and misfolding of the encoded mutant SOD1 protein
leads to synaptic dysfunction (Guo et al., 2000; Magrane et al.,
2012; Fogarty, 2019).
The synapse is the meeting place of communication
between neurons. Synaptic communication breakdown is a
shared phenotype of neurological diseases (Sudhof and Malenka,
2008; Lepeta et al., 2016). Neuron-to-neuron synapses are
composed of a pre-synaptic and post-synaptic compartment,
each with unique proteins and structures to facilitate excitatory
and inhibitory neurotransmission. The neuromuscular junction
(NMJ) is the synapse between a motor neuron and muscle
fibers. It resembles a neuron-neuron synapse, with the presynaptic compartment being the motor neuron terminal and
the post-synaptic compartment being a muscle cell. The NMJs
are ultimately degenerating in all the forms of ALS, including
ALS/FTD, however, here we review the dysfunctions of the
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FIGURE 1

Clinical manifestations and postmortem evidence of synaptic dysfunction in ALS and FTD include loss of dendritic spines and branching
complexity in cortical regions, cortical hyperexcitability prior to the loss of motor neurons, reduction in essential synaptic proteins such as SV2a,
imbalances in excitatory and inhibitory systems, and excess glutamate in patient cerebrospinal ﬂuid (CSF).

Clinical features of central synaptic
dysfunction in patients and patient
samples

models, and C9orf72 ablation models. Reported synaptic
dysfunction phenotypes vary and seem to be dependent upon
cell type, and model age (in vitro or in vivo). The advent
of induced pluripotent stem cells (iPSC) has allowed the
ALS and FTD fields to investigate disease-relevant molecular
pathways on the genetic background of patients, including
the presence of the NRE. These models have paved the way
for mechanistic analyses of temporal synaptic dysfunction in
vitro, and most reported synaptic dysfunctions are within
these models. Moreover, emerging technologies such as multielectrode array (MEA) have since become the gold standard
for studying excitability in vitro and have made probing
the underpinnings of excitability more accessible. There is
variation in the disease phenotypes among the different iPSC
models, possibly due to numerous factors that may include:
differentiation protocols, duration of culture, reagents, purity
of cultures, and origin of iPSC lines. The phenotypic variation
observed in iPSC models has also yielded conflicting results.
Therefore, transparency of reporting culture conditions and
experimental paradigms may help the field reconcile results.
In vivo analyses of synaptic dysfunction in C9-ALS/FTD
has yet to be fully realized but will become necessary for
confirming or denying hypotheses which have been built upon
clinical manifestations and in vitro models. With all this in
mind, the prevailing school of thought is that excitability
and synaptic function are aberrant in a temporal fashion
in C9-ALS/FTD. The underlying mechanisms of synaptic

Clinical evaluation of muscle and neuronal excitability levels
as well as measurement of neurotransmitter systems in the
central nervous system (CNS) of ALS and FTD patients has
yielded critical information regarding the timeline of excitability
events throughout disease progression and has recently been
reviewed elsewhere (Gunes et al., 2020). Changes in excitability
have sparked interest in ALS and FTD for several years.
Published studies in postmortem tissues have provided valuable
clues on the role of neurotransmitter systems, ion channel
dysfunctions, synaptic protein alterations, network connectivity,
and morphological assessments in the pathogenesis of these
diseases. The knowledge has shaped the direction of basic
and translational ALS/FTD research. Figure 1 and Table 1
summarizes evidence of the broad central synaptic dysfunction
observed in ALS and FTD.

Excitability and synaptic activity
Altered synaptic activity and neuronal network excitability
have been reported in ALS/FTD patient-derived neurons
and in C9-NRE-expressing in vivo models, DPR-expressing
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TABLE 1 Evidence of synaptic dysfunctions observed in ALS and FTD patients and postmortem tissue.

Excitatory system

ALS

FTD

• Excess glutamate in CSF (Rothstein et al., 1990; Pioro et al., 1999)

• Autoantibodies to GluA3 in the CSF of FTLD-tau patients and

• Deficient glutamate uptake in the motor cortex, somatosensory
cortex, and spinal cord (Rothstein et al., 1992; Bristol and
Rothstein, 1996)

reduction of the GluA3 protein in the temporal cortex (Palese et al.,
2020)
• Increase in GluA2 subunit protein (Palese et al., 2020)

• Loss of the excitatory amino acid transporter 2 (EAAT2) in
postmortem motor cortex (Bristol and Rothstein, 1996)
• Downregulation of GluN1, GluN2a, GluN2D, GluA2, and GluA3
transcripts (Aronica et al., 2015)

• Reduction in intracortical facilitation in patients with GluA3
autoantibodies (Palese et al., 2020)
• Increase in serine and glutamate in CSF of FTD-patients (Palese
et al., 2020)

• Upregulation of GluA1, GluN2A, and GluN2B in the frontal
cortex, and gene clusters related to neuroinflammation in the spinal
cord (Andres-Benito et al., 2017)
Inhibitory system

• Loss of parvalbumin interneurons (Nihei et al., 1993)

• TMS studies indicate deficits in the inhibitory system in FTD

• Reduction in GABAergic inhibition in the motor cortex (Turner

(Benussi et al., 2017)

et al., 2005; Foerster et al., 2012)
• Reduction of GABAα1 transcripts in postmortem motor, frontal,
and temporal cortices (Petri et al., 2006)
• Elevated GABAβ1 subunit mRNA in the motor cortex, and mRNA
for the enzyme glutamic acid decarboxylase (GAD) is elevated in
frontal and temporal cortices (Petri et al., 2003, 2006)
• Upregulation of GABBRA1, GABBR2 in frontal cortex
(Andres-Benito et al., 2017)
Synaptic proteins

• Decreased levels of the trans-synaptic organizer neuronal pentraxin

• Neuronally derived exosomes isolated from FTD patient plasma

receptor (NPTXR) in C9-FTD vs. C9-NRE carriers, which is a

have reduced levels of synaptotagmin, synaptophysin, and

trans-synaptic organizer of excitatory and inhibitory synapses

neurogranin, and increase of pre-synaptic synapsin-1 protein

(Barschke et al., 2020)

(Goetzl et al., 2016)

• Pre-symptomatic C9-NRE mutation carriers, PET imaging with
[11 C] UCB-J, which binds to the synaptic vesicle protein, SV2A,
revealed a synaptic loss in the thalamus before symptom onset
(Malpetti et al., 2021)
Morphological defects

• Apical dendrites, in addition to the cell bodies of Betz cells in layer
V degenerate in the cortex of ALS patients (Udaka et al., 1986)
• Apical dendrite degeneration of Betz cells in fALS, sALS, and
FTD-ALS (Genc et al., 2017)

• Decreased density of dendritic spines on layer III pyramidal cells in
the postmortem cortex (Catala et al., 1988; Ferrer, 1999),
• Degeneration of dendrites of the dentate gyrus (Terreros-Roncal
et al., 2019)

• Significant reduction in the number of synapses in motor cortex
(Genc et al., 2017)

• Severe reduction in dendritic arborization and spine density in
upper cortical layers (Ferrer et al., 1991)

• Loss of synapses in pre-frontal cortex correlating with severity of
cognitive impairment (Henstridge et al., 2018)
• Selective loss of tripartite synapses in the spinal cord of C9-NRE
patients (Broadhead et al., 2022)
Functional studies

• Cortical hyperexcitability is observed in ALS patients (Eisen et al.,
1993; Kanai et al., 2006; Vucic and Kiernan, 2006; Vucic et al., 2008;

• Hyperexcitability is yet not observed in the C9-FTD patient
populations (Schanz et al., 2016)

Bae et al., 2013; Geevasinga et al., 2015, 2016; Wainger and
Cudkowicz, 2015; Walhout et al., 2015; Schanz et al., 2016; Brunet
et al., 2020; Menon et al., 2020).
These dysfunctions include defects in excitatory and inhibitory neurotransmitter systems, and changes in synaptic protein levels.
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FIGURE 2

Synaptic dysfunctions observed in patient-derived in vitro models of C9-ALS/FTD include Ca2+ -buffering deﬁcits and increased vulnerability to
glutamatergic insult, deﬁcits in the activity-dependent transcriptome, decreased complexity of dendritic arborization and loss of dendritic
spines, temporal phases of excitability alterations, and increased DPR levels as a result of hyperexcitation.

2022). Additionally, at the time point at which hyperexcitability
was observed in the C9-NRE MNs, this group observed a higher
number of neurons double-labeled with Beta-tubulin III and
SMI-32, pan-neuronal and motor neuron markers, respectively,
which may impact connectivity and excitability in these cultures
(Burley et al., 2022). One group reported an increase in the
frequency-current (F-I) relationship in C9-NRE iPSC MNs early
in culture, but then eventual loss of action potential (AP) firing,
without alterations in overall viability of these cultures (Devlin
et al., 2015). The cultures used in the Devlin et al. study had
similar ratios of motor neurons and astrocytes as in the Burley
et al. study, allowing for more direct comparison of these studies.
A progressive loss of voltage-gated sodium (Na+ ) and K+
currents is also associated with the loss of excitability of these
cultures (Devlin et al., 2015). Similarly, under current-clamping
conditions, another group showed that C9-NRE iPSC MNs
produce fewer spikes with progressive current injection (Sareen
et al., 2013). However, these cultures were not assessed over time
to pinpoint the timeline of changes in excitability (Sareen et al.,
2013). These cultures exhibited similar purity of motor neurons
and glial populations (20–30%) as other studies previously
described. Sareen et al. (2013) correlated hypoexcitability to
RNA sequencing (RNA-seq) results which showed an increase
in expression of KCNQ3 (Potassium Voltage-Gated Channel
Subfamily Q Member 3) in C9-NRE iPSC MNs. Another study
showed that at earlier time points in culture, C9-NRE iPSC
MNs do produce more APs with increasing injected current
when compared to healthy control MNs (Burley et al., 2022).
Conversely, in other studies, no changes in firing properties,

dysfunction and neuronal excitability continue to be a significant
focus of research.

Patient-derived neuronal models
Multiple studies have reported changes in neuronal
excitability in C9-ALS/FTD patient-derived induced pluripotent
stem cell (iPSC) neurons throughout the duration of cell culture
in vitro. Some of these cultures exhibit hyperexcitability in early
stages, which transitions to hypoexcitability in later days of
culture (Figure 2) (Wainger et al., 2014; Devlin et al., 2015;
Burley et al., 2022). Relatively young C9-ALS/FTD iPSC motor
neurons (MNs) display hyperexcitability, namely a higher mean
firing rate (Hz) and higher spikes per minute, measured by
multi-electrode array (MEA) recordings, an effect that could be
reversed by application of retigabine, a voltage-gated potassium
(K+ ) channel (Kv7) agonist (Wainger et al., 2014). In this study,
the authors ensured MEA recordings were taken only from
motor neurons by utilizing a motor neuron-specific fluorescent
reporter and purifying using fluorescence-activated cell sorting
(FACS). In-line with this, the shift from hyper- to normal or
hypo- excitability in C9-NRE iPSC MNs has recently been
observed to occur transiently and at early days in culture;
hyperexcitability of C9-NRE MNs at earlier stages in vitro, with
firing rates of control and C9-NRE MNs becoming equal once
cultured further (Burley et al., 2022). It is important to note that
the iPSC MNs used in this study are not pure MNs; the authors
quantify the presence of astrocytes to be ∼20% (Burley et al.,
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F-I relationship, or Na+ or K+ channel currents were detected
in C9-ALS iPSC MNs, which the authors attribute to a lack of
glia in their cultures (Selvaraj et al., 2018). Indeed, this group
performed a follow-up study investigating non-cell autonomous
effects of glia on MN excitability. When healthy MNs were
cultured with C9-NRE astrocytes, a progressive loss of action
potential firing resulted (Zhao et al., 2020). Once further
cultured, healthy motor neurons grown with C9-NRE astrocytes
progressively lost Na+ or K+ channel currents (Zhao et al.,
2020). Many groups have shown the potential causal role of
ion channel expression or function in mediating temporal
excitability in iPSC MNs, and this topic has been recently
reviewed (Lorusso et al., 2019). Hyperexcitability has also
been observed in C9-NRE iPSC cortical neurons (CNs); an
increase in the rate of burst firing (reduction of inter-burst
length), measured with the whole-cell patch-clamp technique
and MEA recordings (Perkins et al., 2021). Also, an increase in
miniature excitatory postsynaptic currents (mEPSCs) without
changes in excitatory glutamate receptor response in addition
to a reduced ready-releasable pool (RRP) of synaptic vesicles
(Perkins et al., 2021). The CNs used in the Perkins et al. study
were estimated to be 90–98.5% pure cortical neurons and thus
the synaptic dysfunction measured can be attributed to neuronal
intrinsic mechanisms (Perkins et al., 2021). Based on present
reports, C9-NRE MNs show changes in excitability and ionic
currents, in addition to temporal changes in synaptic activity.
Currently, only alterations in firing rate, but not changes in ionic
currents (Na+ and K+ ) have been reported in C9-NRE CNs. To
conclude, alterations in excitability of C9-NRE neurons may be
intrinsic or non-cell autonomous, as there are studies supporting
both postulates.
Deficits in calcium (Ca2+ ) buffering and signaling are
known to be associated with neurodegeneration (Marambaud
et al., 2009), in addition to glutamate vulnerability (Foran
and Trotti, 2009). Although not specific to C9-NRE ALS/FTD,
early work has linked cortical hyperexcitability in ALS with
disruptions in the excitatory system (Figure 1). Indeed, excess
glutamate has been measured in CSF of ALS patients (Rothstein
et al., 1990) and low glutamate uptake in the motor cortex,
somatosensory cortex, and spinal cord (Rothstein et al., 1992;
Bristol and Rothstein, 1996) have been attributed to the
loss of the excitatory amino acid transporter 2 (EAAT2) in
motor cortex of ALS patients (Bristol and Rothstein, 1996).
Alterations in glutamate receptor subunit composition and
changes in the properties of these subunits have also been
identified in ALS. The RNA-editing enzyme ADAR2, a doublestrand RNA-specific deaminase, typically edits the Q/R site
of AMPA receptor (AMPAR) subunit GluA2, which dictates
the calcium permeability of the AMPAR complex (Kwak and
Kawahara, 2005). However, in ALS patient tissue, a loss of
RNA-editing at this site makes the AMPARs permeable to
calcium and the neurons susceptible to excitotoxicity (Kwak and
Kawahara, 2005). Based on evidence from C9-NRE iPSC models,

Frontiers in Molecular Neuroscience

it is not clear that excess synaptic glutamate is responsible
for the hyperexcitability observed in vitro, and alterations to
glutamate receptor composition, function, and expression are
not ubiquitously reported. Deficits in this regard are observed in
C9-ALS/FTD patient-derived iPSC neurons (Figure 2). Dafinca
et al. reported alterations in calcium dynamics via Ca2+ imaging
in C9-NRE MNs. In this study, C9-NRE MNs have higher
Ca2+ levels at rest, and potassium chloride (KCl) evokes an
increased amplitude of response compared with control iPSC
MNs. In contrast, stimulation with glutamate evoked a lesser
amplitude of response but induced a prolonged period of Ca2+
waves in the diseased motor neurons (Dafinca et al., 2020).
The recovery time post-stimulation with KCl and glutamate
is delayed in the C9-NRE MNs (Dafinca et al., 2020). These
phenotypes were observed in tandem with increased Ca2+ permeable GluA3, GluA2, and GluN2A subunits in the C9NRE MNs (Dafinca et al., 2020). Higher sensitivity to glutamate
and thus glutamate-induced excitotoxicity is corroborated by
previous studies in C9-NRE MNs (Donnelly et al., 2013; Selvaraj
et al., 2018; Shi et al., 2018). Studies employing RNA-seq
of C9-NRE MNs found a significant upregulation of GluA1
transcripts and protein levels compared to healthy controls,
which the authors found led to a lower threshold for glutamateinduced excitotoxicity (Selvaraj et al., 2018). Additionally,
upregulation of GluA1 mRNA in ALS-patient spinal cord tissue,
but not frontal cortex, was also observed, corroborating in
vitro results (Selvaraj et al., 2018). Another study did find
increases in GluN1 and GluA1 in postmortem motor cortex
(Shi et al., 2018). In C9-NRE MNs at a time point when
hyperexcitability is observed, ionomycin provokes a greater delta
peak amplitude via Ca2+ imaging, which is not observed 7
days later when these cultures are hypoexcitable (Burley et al.,
2022), suggesting intracellular calcium release has a role in
propagating hyperexcitability. Another study showed that C9NRE MNs have increased spikes (Ca2+ events) per second at
baseline (Bursch et al., 2019). Both of these studies also showed
deficits in mitochondrial Ca2+ buffering; an increase in Ca2+
release from mitochondria in C9-NRE MNs upon application of
FCCP (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone,
a mitochondrial oxidative phosphorylation uncoupler) (Bursch
et al., 2019), and a reduction of Ca2+ uptake into mitochondria
after glutamate stimulation (Dafinca et al., 2020). As calcium
is a second messenger, disruptions in intracellular Ca2+ levels
have clear implications on Ca2+ -dependent pathways and thus
impact many cellular and molecular processes (Marambaud
et al., 2009).

Other models
In addition to patient-derived iPSC neuron models in which
potentially all of the pathogenic mechanisms (expression of
NRE-RNA, DPRs, and loss of C9orf72) could contribute to
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upward shift in the F-I relationship, which was unique to the
motor cortex and not observed in somatosensory or visual
cortices (Jo et al., 2022). In this study, Jo et al. determined the
cause of hyperexcitability in these experiments to be due to
persistent Na+ currents, which could be reversed by applying a
therapeutic dose of Riluzole or antibodies targeting specific Na+
channel subunits (Jo et al., 2022). Expression of poly(PR)36 in
Drosophila melanogaster larvae increases extracellular glutamate
and intracellular Ca2+ (Xu and Xu, 2018). The discordance of
these overall results may be due to DPR species, length, or timing
of expression or exposure to the DPRs.
Recently, our laboratory has provided evidence that aberrant
neuronal activity and synaptic dysfunction in C9-ALS/FTD is
a component of a feedforward loop. In C9-NRE iPSC MN
and rat primary cortical and motor neurons, high-frequency
stimulation via optogenetics or glutamate bath increases levels
of all DPR species (Figure 2) (Westergard et al., 2019). This
effect can be diminished by glutamate receptor antagonists
(Westergard et al., 2019). Another group recently corroborated
our findings, showing that excitatory optogenetic stimulation
increases poly(GA) levels in rat primary cortical neurons
(Catanese et al., 2021). Furthermore, Catanese et al. showed that
the application of Apamin, a Kv7 inhibitor and a compound
that inhibits Ca2+ -activated potassium (SK) channels, can
reduce this burden of poly(GA) (Catanese et al., 2021). These
potassium channel inhibitors also reduced levels of apoptotic
markers in C9-NRE MNs (Catanese et al., 2021), similar to
other findings (Wainger et al., 2014). The neurons in this
study are likely hyperexcitable due to the use of potassium
channel inhibitors, and counterintuitively, this state of neuronal
activity was shown to be beneficial. Intriguingly, 1 Hz neuronal
inhibition via activation of archaerhodopsin, an outwardly
directed proton pump that silences neurons, leads to apoptotic
cell death of poly(GA) expressing neurons (Catanese et al.,
2021), which suggests a goldilocks dilemma for types of neuronal
activity in disease. There is also the possibility that modes of
neuronal activity are beneficial or detrimental in a cell-typespecific manner. These latter studies were performed in rat
primary cortical neurons, and hyperexcitability in vitro has been
primarily reported in patient-derived iPSC MNs.
Alterations in synaptic activity and electrophysiological
properties due to a loss of C9orf72 protein have also been
reported. In zebrafish, reduction of C9orf72 protein leads to
reduction of quantal release and frequency of mEPCs (miniature
endplate currents) at the neuromuscular junction and delays in
synaptic vesicle recycling (Butti et al., 2021). Complete ablation
of C9orf72 leads to deficits in long-term potentiation (LTP) at the
dentate gyrus and long-term depression (LTD) at the Schaffer
collateral (Ho et al., 2020). LTP and LTD are the most-studied
forms of synaptic plasticity that are important in learning
and memory (Malenka and Bear, 2004), which are aspects of
cognition affected in ALS/FTD. Loss of C9orf72 protein also
leads to a reduction in mEPSC frequency in mouse hippocampal

phenotypes, there are other models in which only one or two
of these pathological phenomena are present. By transducing
the NRE-RNA, using artificial constructs to express DPRs, or
utilizing C9orf72 knock-out models in vitro and in vivo, the
contribution of each of these pathological mechanisms can be
determined separately and in conjunction.
Overall, there are few reports of synaptic dysfunction in
rodent models of the C9-NRE. Intriguingly, in a rodent model
of C9-ALS/FTD, mice with a bacterial artificial chromosome
(BAC), in which there is C9-NRE RNA in addition to DPRs,
show loss of interneurons in the spinal cord (Liu et al.,
2016) at end-stage points. Corroborating the occurance of
synaptic dysfunction in this C9-BAC mouse model, another
group reported that before disease onset, there is a decrease
in inhibitory signaling in layer V of the motor cortex and
increased output of pyramidal neurons in layer V (Amalyan
et al., 2022). Conversely, in other C9-NRE BAC mice, there
were no differences in excitability, Ca2+ transients, or sensitivity
to glutamate (O’rourke et al., 2015). In hippocampal neuron
cultures, with an expression of 66 x NRE repeats and levels
of detectable poly(GP), there was an increased amplitude of
response to glutamate and KCl via Ca2+ imaging, in addition
to increased sensitivity to glutamate-mediated cell death (Huber
et al., 2022). Through pharmacological inhibition, the authors
determined the glutamate vulnerability was due to extrasynaptic NMDARs (Huber et al., 2022). These deficits correlated
with a reduction in dendritic arborization complexity, total
dendrite length, the number of branches, and fewer mature
dendritic spines (Huber et al., 2022). Dendritic spines are
thought to compartmentalize Ca2+ (Yuste et al., 2000), and thus,
the loss of these compartments may result in an inability to
buffer intracellular Ca2+ . Results in hippocampal cultures could
point to aberrations that may tilt the scale more toward FTD
clinical phenotypes vs. pure ALS phenotypes.
Electrophysiological properties of neurons are also altered
with the expression of DPRs; however, these alterations are
not consistently in agreement. In some cases, the expression
of DPRs leads to reductions in synaptic transmission and
synaptic unloading. In poly(GA)50 -expressing rat primary
cortical neuron cultures, a reduction of synaptic unloading
and simultaneous increase in Ca2+ influx was reported by
Jensen et al., which led to the identification of decreased levels
of the synaptic vesicle protein SV2a (Jensen et al., 2020).
In vivo models of DPR expression also show evidence of
electrophysiological alterations. Layer V pyramidal neurons of
the prefrontal cortex of 4.5-month-old mice which express
poly(GR)80 have significantly fewer frequency of mEPSCs
without modifications in AMPAR activity (Choi et al., 2019).
Conversely, some studies show increased excitability in the
presence of DPRs. Poly(PR) exhibits hyperexcitable effects in
layer V pyramidal neurons. Motor cortex slices incubated with
100 nM of synthetic poly(PR)20 exhibit increased frequency of
firing, a reduction in threshold to fire AP (rheobase), and an
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cultures (Bauer et al., 2022). In the cortex of C9 knockout mice,
there are increased levels of the AMPAR subunit GluA1, which
the authors link to enhanced excitotoxicity (Xiao et al., 2019).
C9-NRE iPSC MNs and C9 knockout iPSC MNs, which both
have reduced levels of C9orf72 protein, are more sensitive to
glutamate excitotoxicity and have increased surface expression
of GluN1 (Shi et al., 2018). This phenotype can be rescued by
the replacement of C9orf72 protein or the use of retigabine, an
activator of the voltage-gated potassium channel, Kv7, (Shi et al.,
2018), which has been previously shown to promote C9-NRE
iPSC MNs survival and reduce hyperexcitable cultures (Wainger
et al., 2014).
Isolating each pathological mechanism of C9-ALS/FTD still
results in synaptic dysfunction; however, it is important to note
that the expression of NRE-RNA may allow RAN translation
to occur. Therefore, DPRs may also be present in this type
of model.

et al., 2021). Alternatively, another study that performed RNAseq on C9-NRE MNs revealed via gene ontology analysis that
mRNAs encoding synaptic proteins are downregulated in
C9-NRE MNs (Selvaraj et al., 2018). These synaptic mRNAs
include KCNJ2, an inwardly rectifying potassium channel,
synaptotagmin-5 (SYT5), and NMDAR subunit GRIN3B
(Selvaraj et al., 2018). In a recent transcriptomics study of
C9-NRE iPSC MNs, an analysis of potential transcriptional
regulators of the differentially expressed transcripts showed
that the transcripts that are upregulated in C9-NRE MNs are
likely driven by the AP-1 transcription factor complex, which
is comprised of FOS and JUN heterodimers (Neuro et al.,
2021) and is known to be regulated by neuronal activity or
other stimuli (Kaminska et al., 2000). Given that increased
usage of the AP-1 transcription factor complex could be
reflective of a hyperexcitable state, regulation and maintenance
of synapses could be directly affected by overactivation of
the activity-dependent transcription pathway. Based on the
detailed case for hyperexcitability presented for C9-ALS/FTD
earlier in this review, investigations into alterations in the
activity-dependent transcriptome within patient-derived cells
are of interest and an active avenue of research in our laboratory
and others. A recent study showed age-dependent dysregulation
of the activity-dependent transcription factor, cAMP/Ca2+
response element-binding protein (CREB) in C9-NRE iPSC
MNs (Catanese et al., 2021). In the early stages, there were
elevated levels of phosphorylated (active) CREB in the C9-NRE
iPSC MNs, which matched the hyperexcitable state of the
culture (Catanese et al., 2021). This transitioned to a loss
of CREB activity when the cultures became hypoexcitable
(Catanese et al., 2021). These phenomena were also observed
in rat primary cortical neurons expressing poly(GA)175; at
early stages of culture there was increased p-CREB, with
progressive loss of p-CREB when cultured further. The loss of
CREB activity correlated with the downregulation of synaptic
genes, including synaptotagmin-1 and neuroligin-3, and also
a loss of synapses (Catanese et al., 2021). Inhibition of Kv7
and SK potassium channels were found to be neuroprotective,
and restored CREB transcriptional activity and levels of
synaptic RNAs regulated by CREB (Catanese et al., 2021).
This study provides further evidence of dysregulation of
the activity-dependent transcriptome in ALS/FTD neurons.
Patient-derived cortical neurons also show defects in synaptic
transcripts, as RNA-seq revealed a reduction of Protocadherin
Gamma Subfamily C 4 (PCDHGC4), which is a synaptic
protein that negatively regulates neuroligin-1, and thus
controls synapse number, and indeed these neurons had an
increased excitatory synaptic density; increase in colocalized
pre-synaptic marker synapsin-1 and post-synaptic marker
PSD-95 (Perkins et al., 2021).

Regulation and alteration of synaptic
proteins
Due to the alterations in overall synaptic function
associated with the C9 mutation, it is conceivable that
C9orf72 has a direct or indirect synaptic function. Indeed,
the C9orf72 protein is found to have a synaptic localization
(Frick et al., 2018; Xiao et al., 2019), but its precise role at
the synapse is not yet clear. C9-ALS/FTD in vitro models
show aberrations in synaptic transcripts and protein
levels in addition to morphological defects. This section
highlights the implication of the C9-NRE, DPRs, and loss
of C9orf72 protein on gross morphological phenotypes and
synaptic proteins.

Patient-derived neuronal models
Models of C9-ALS/FTD have shown alterations in several
cellular pathways, such as nucleocytoplasmic transport,
proteostatic imbalance, RNA metabolism, and inflammation
(Haeusler et al., 2016; Balendra and Isaacs, 2018; Cicardi et al.,
2021), but synaptic pathways and gene networks have been
consistently identified as aberrant. From RNA-seq experiments
on C9-NRE MNs, there was upregulation of synaptic proteins
Dipeptidyl Peptidase Like 6 (DPP6) and its interactor, Potassium
Voltage-Gated Channel Subfamily Q Member 3 (KCNQ3), as
well as cerebellin family proteins CBLN1, CBLN2, and CBLN4
(Sareen et al., 2013). One such synaptic transcript, CBLN1 was
also recently identified to be downregulated in C9-NRE CNs,
indicating potential divergence in synaptic components (Perkins
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Other models

branching and dendritic spine composition. Indeed, alterations
in dendritic spines in relation to the C9-NRE have been observed
as described (May et al., 2014; Burguete et al., 2015), and in
neurites, the C9-NRE repeats can be bound by the activityregulated RNA-binding protein, Fragile-X mental retardation
protein (FMRP) and are neuritically localized (Burguete et al.,
2015). Thus, the intronic region of the C9orf72 gene may serve
as a synaptic localization signal. Along these lines, C9orf72 has
been shown to interact with synaptic proteins SV2a (Butti et al.,
2021), PSD-95 (Xiao et al., 2019), and the synapsin family of
proteins (Bauer et al., 2022), in addition to endosomes (Shi et al.,
2018), and regulates lysosomal biogenesis in motor neurons
further highlighting the potential role of C9orf72 protein at
the synapse. NRE-RNAs or DPRs at synaptic sites may also
impair local neuritic or synaptic translation, thus inhibiting
cytoskeletal remodeling and maintenance. A reduction in axon
length was also observed due to the knockdown of C9 protein
(Sivadasan et al., 2016). The authors of this study link the role
of C9orf72 in the endosome-lysosome pathway to increased
expression of glutamate receptors. In the motor cortex of C9KO mice, loss of C9 protein in microglia leads to enhanced
synaptic pruning, an increase in complement cascade factor
C1q, detectable synaptophysin signal engulfed by microglia, and
a loss of vGlut1 and synaptophysin (Lall et al., 2021). It is
important to note that while C9orf72 protein is localized at
the synapse, it also plays are role in membrane trafficking and
autophagic regulation, and this role has recently been reviewed
elsewhere (Tang, 2016). Thus, whether or not the synaptic
deficits observed with the loss of C9orf72 is direct or indirect
has yet to be seen. Considering all of these studies, the C9-NRE,
DPRs, and loss of C9orf72 lead to aberrant excitability detailed
in the section above, broadly changing the synaptic landscape.

In addition to alterations in synaptic transcripts and protein
levels, the gain-of-function (NRE-RNA, DPRs) and loss-offunction (loss of C9orf72 protein) mechanisms of the C9NRE lead to defects in synaptic morphology, namely a loss of
synapses and loss of dendritic arborization complexity. In rat
primary cortical and motor neuron cultures, in conjunction
with poly(GA) overexpression, a loss of the synaptic vesicle
protein, SV2a, was observed (Jensen et al., 2020). This loss
of SV2a was also seen when animals expressing poly(GA)149
were examined in the spinal cord and at the NMJ (Jensen
et al., 2020). Mice that express poly(GR)80 under a CamKII
promoter postnatally undergo DPR accumulation in an agedependent manner (Choi et al., 2019). In these mice at 6 months
of age, an age where poly(GR) starts to accumulate, there is
a significant reduction in PSD-95 protein in cortical regions
(Choi et al., 2019). Drosophila melanogaster expressing either
C9-NRE repeats or DPRs show decreased dendritic arborization
complexity and reduced synaptic boutons (Burguete et al., 2015;
Perry et al., 2017; Park et al., 2020). This phenomenon has been
corroborated in mice (May et al., 2014). More severe deficits in
dendritic branching are seen with arginine-containing DPRs and
neuritic localization of the NRE-RNA, suggesting a more drastic
effect at synaptic sites (Burguete et al., 2015; Park et al., 2020).
At the NMJ, the expression of NRE-RNA reduces the number of
NMJ active zones and synaptic boutons in fly larvae (Freibaum
et al., 2015; Zhang et al., 2015).
Furthermore, as C9orf72 is known to be localized to
synaptic regions (Xiao et al., 2019), there is the possibility
that C9orf72 has a function at the synapse. Strengthening
this argument, partial or complete ablation of C9orf72 has
consequences on synaptic proteins and structure, in addition
to electrophysiological properties discussed above. Loss of C9
protein leads to a reduction in localization of pre-and postsynaptic markers at the NMJ of zebrafish and a reduction
of synapse size (Butti et al., 2021). In C9-knockout (C9KO) mouse cortex, there is a loss of complexity of dendrite
arborization, a reduction in the total length of the dendrites,
and a reduction of spine density (Ho et al., 2019; Lall et al.,
2021). A drop in synaptic Rab proteins, such as Rab39b, is
also observed in the C9-KO mouse cortex (Xiao et al., 2019).
Most recently, knockdown of C9orf72 protein led to a reduction
in excitatory synapses in primary rat hippocampal cultures
(Bauer et al., 2022). In this study, loss of C9orf72 protein
levels was concordant with loss of synapsin-1, synapsin-3 and
SV2 (Bauer et al., 2022). In a proteomics screen, the C9orf72
protein interacted with cofilin, a protein that regulates the
actin cytoskeleton (Sivadasan et al., 2016). Dendritic spines
are composed primarily of actin (Hering and Sheng, 2001),
therefore, C9orf72 may play a role in regulating dendritic
spine dynamics through these interactions. Disruptions in the
C9orf72-cofilin interaction may lead to deficits in dendritic
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Discussion and conclusion
Communication breakdown at the synaptic level has been
observed in many genetic and sporadic forms of ALS and FTD.
These breakdowns include electrophysiological alterations,
excitatory and inhibitory neurotransmitter system defects,
such as glutamate or GABA receptor subunit expression,
pre- and post-synaptic protein expression, and ion channel
dysregulation. In addition to the reported C9orf72-linked
cortical hyperexcitability observed early in the disease timeline
(Geevasinga et al., 2015; Wainger and Cudkowicz, 2015; Schanz
et al., 2016), a few case studies have revealed that epilepsy can
co-occur with C9-FTD (Melis et al., 2022), and C9-ALS (van den
Ameele et al., 2018). Epilepsy is a manifestation of synchronous
or excessive neuronal activity (Devinsky et al., 2018) and thus
intersects with what is known regarding excitability in ALS/FTD.
While this review has focused on the synaptic dysfunctions
associated with the C9-NRE, synaptic deficits are also observed
in other genetic forms of ALS/FTD. Synaptic dysfunction as a
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result of SOD1 mutations is widely reported (Kuo et al., 2005;
Bories et al., 2007; Pieri et al., 2009; Magrane et al., 2012).
Mutations in TDP-43, in addition to nuclear loss of TDP43, can lead to a myriad of synaptic dysfunctions which vary
based on region of mutation (Fogarty et al., 2016; Chand et al.,
2018; Dafinca et al., 2020; Dyer et al., 2021; Ni et al., 2021).
Similarly, mutations in FUS and/or nuclear loss of FUS leads
to changes in excitability and synaptic function (Armstrong and
Drapeau, 2013; Sephton et al., 2014; Sahadevan et al., 2021;
Scekic-Zahirovic et al., 2021). Overall, it has become clear that
genes causative of ALS and FTD, including C9orf72, either have
a function at the synapse or are associated with altered synaptic
function when mutated. Changes in synaptic morphology,
function, and expression of synaptic proteins are often an early
observed phenomenon; it would be advantageous to determine
mechanistic events that perpetuate synaptic dysfunction to
develop treatments that can be used in a therapeutic window.
An upstream event that may perpetuate disease progression
is alterations in the activity-dependent transcriptome (Figure 2).
It could be that mutations in ALS/FTD genes of interest cause
changes in transcription factor complex binding, levels of
transcription factor proteins, or activity-dependent epigenetic
modifications, therefore activating or suppressing genes
required for synaptic maintenance or remodeling. There is
also the potential that the pathway is hyper- or hypo-activated
due to aberrant activity or protein aggregates observed in
patients. Indeed, it is known that in Alzheimer’s disease
(AD), the activity-dependent transcription factor cAMP/Ca2+
response element-binding protein (CREB) is downregulated
in patient brain tissue and is inversely related to amyloidbeta plaques, one of the significant hallmarks of the disease
(Pugazhenthi et al., 2011). Furthermore, targets of CREB,
which are linked to cognition and memory, are reduced and
are proposed to be mediated by the amyloid-beta aggregates
(Espana et al., 2010). Indeed, a recent study identified agedependent CREB dysfunction in C9-NRE iPSC MNs (Catanese
et al., 2021). Other activity-dependent pathways, such as
regulation of local synaptic translation (Holt et al., 2019),
could also be impacted by protein aggregation and aberrant
neuronal activity.
Synaptic dysfunction in ALS and FTD presents a causality
dilemma. It is currently unknown if synaptic dysfunction is
causal to neuron death in ALS and FTD or if neurodegeneration
causes synaptic dysfunction. There is also the possibility
that a triggering event can induce a feed-forward loop
of neurodegeneration and synaptic dysfunction in sequence.
Clinical evidence shows us that aberrations in neuronal activity
(cortical hyperexcitability) may be an early event or at least
occurs before significant degeneration of the corticospinal tract
(Vucic et al., 2008). Still, it is unclear what triggers this initial
event, if it is an early event. Identifying the chicken and the egg
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in the scenario of synaptic dysfunction in ALS and FTD will
become essential.
In summary, morphological defects, functional defects,
neurotransmitter receptor changes, as well as changes
in synaptic mRNAs and proteins are associated with the
neurodegenerative diseases ALS and FTD. Neurons are the
ultimate cell type affected in these diseases. Thus, the features
which define neurons: synaptic connections, and chemical
and electrical activities, are valuable modalities worth focusing
current and future research on.
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